{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:52:15Z","timestamp":1790488335737,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T00:00:00Z","timestamp":1690675200000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.pharmthera.2022.108257","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T11:24:16Z","timestamp":1659007456000},"page":"108257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases"],"prefix":"10.1016","volume":"237","author":[{"given":"Kawthar","family":"Dhayni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Zibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawra","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00efd","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pharmthera.2022.108257_bb0005","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1161\/ATVBAHA.107.147009","article-title":"CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration","volume":"27","author":"Abu Nabah","year":"2007","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108257_bb0010","first-page":"5269","article-title":"The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity","volume":"165","author":"Addison","year":"2000","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"5 Suppl","key":"10.1016\/j.pharmthera.2022.108257_bb0015","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1097\/00003246-200205001-00005","article-title":"Endothelial responses to mechanical stress: Where is the mechanosensor?","volume":"30","author":"Ali","year":"2002","journal-title":"Critical Care Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/ng.2962","article-title":"Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits","volume":"46","author":"Auer","year":"2014","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.113.007724","article-title":"International union of basic and clinical pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors","volume":"66","author":"Bachelerie","year":"2014","journal-title":"Pharmacological Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0030","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/79767","article-title":"Regulation of tyrosine kinase activation and granule release through \u03b2-arrestin by CXCR1","volume":"1","author":"Barlic","year":"2000","journal-title":"Nature Immunology"},{"issue":"23","key":"10.1016\/j.pharmthera.2022.108257_bb0035","doi-asserted-by":"crossref","first-page":"16287","DOI":"10.1074\/jbc.274.23.16287","article-title":"\u03b2-Arrestins regulate Interleukin-8-induced CXCR1 internalization","volume":"274","author":"Barlic","year":"1999","journal-title":"Journal of Biological Chemistry"},{"issue":"45","key":"10.1016\/j.pharmthera.2022.108257_bb0040","doi-asserted-by":"crossref","first-page":"30868","DOI":"10.1074\/jbc.M804054200","article-title":"The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis","volume":"283","author":"Baugher","year":"2008","journal-title":"The Journal of Biological Chemistry"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108257_bb0045","first-page":"6931","article-title":"CXCR2\/CXCR2 ligand biology during lung transplant ischemia-reperfusion injury","volume":"175","author":"Belperio","year":"2005","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"32","key":"10.1016\/j.pharmthera.2022.108257_bb0050","doi-asserted-by":"crossref","first-page":"11791","DOI":"10.1073\/pnas.0402090101","article-title":"Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: Prevention of reperfusion injury","volume":"101","author":"Bertini","year":"2004","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb2000","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nm1567","article-title":"MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment","volume":"13","author":"Bernhagen","year":"2007","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1476-5381.2011.01566.x","article-title":"Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1\/CXCR2 non-competitive allosteric inhibitor","volume":"165","author":"Bertini","year":"2012","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108257_bb0060","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2353\/ajpath.2006.040748","article-title":"Up-regulated expression of the CXCR2 Ligand KC\/GRO-\u03b1 in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression","volume":"168","author":"Boisvert","year":"2006","journal-title":"The American Journal of Pathology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1172\/JCI1195","article-title":"A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice","volume":"101","author":"Boisvert","year":"1998","journal-title":"The Journal of Clinical Investigation"},{"issue":"19","key":"10.1016\/j.pharmthera.2022.108257_bb0070","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.106.660472","article-title":"Perivascular mast cells promote atherogenesis and induce plaque destabilization in apolipoprotein E-deficient mice","volume":"115","author":"Bot","year":"2007","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108257_bb0075","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/ndt\/gfy325","article-title":"Endothelial cells exposed to phosphate and indoxyl sulphate promote vascular calcification through interleukin-8 secretion","volume":"34","author":"Bouabdallah","year":"2019","journal-title":"Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1476-5381.2009.00182.x","article-title":"SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor","volume":"158","author":"Bradley","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.brainres.2010.11.087","article-title":"Chemokine-related gene expression in the brain following ischemic stroke: No role for CXCR2 in outcome","volume":"1372","author":"Brait","year":"2011","journal-title":"Brain Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1165\/rcmb.2017-0214OC","article-title":"Myeloid-derived suppressor cells are necessary for development of pulmonary hypertension","volume":"58","author":"Bryant","year":"2018","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"issue":"17","key":"10.1016\/j.pharmthera.2022.108257_bb0095","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1182\/blood-2011-05-347393","article-title":"Attenuation of leukocyte recruitment via CXCR1\/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II","volume":"118","author":"Burton","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0100","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/039463200501800307","article-title":"Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric noncompetitive inhibitor of CXCL8 receptors: A therapeutic approach for the treatment of post-ischemic hepatic syndromes","volume":"18","author":"Cavalieri","year":"2005","journal-title":"International Journal of Immunopathology and Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1124\/jpet.106.119040","article-title":"A novel, orally active CXCR1\/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation","volume":"322","author":"Chapman","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0110","first-page":"2587","article-title":"Regulation of the expression of IL-8 receptor A\/B by IL-8: Possible functions of each receptor","volume":"155","author":"Chuntharapai","year":"1995","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108257_bb0115","first-page":"5682","article-title":"Monoclonal antibodies detect different distribution patterns of IL-8 receptor A and IL-8 receptor B on human peripheral blood leukocytes","volume":"153","author":"Chuntharapai","year":"1994","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0120","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.24028","article-title":"CXC chemokine receptor-1 is expressed by hepatocytes and regulates liver recovery after hepatic ischemia\/reperfusion injury","volume":"53","author":"Clarke","year":"2011","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neulet.2015.08.041","article-title":"ELR-CXC chemokine antagonism is neuroprotective in a rat model of ischemic stroke","volume":"606","author":"Connell","year":"2015","journal-title":"Neuroscience Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0130","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/j.1523-1755.2005.00272.x","article-title":"Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia\/reperfusion","volume":"67","author":"Cugini","year":"2005","journal-title":"Kidney International"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40268-018-0236-x","article-title":"Pharmacokinetics of the oral selective CXCR2 antagonist AZD5069: A summary of eight phase I studies in healthy volunteers","volume":"18","author":"Cullberg","year":"2018","journal-title":"Drugs in R&D"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108257_bb0140","doi-asserted-by":"crossref","first-page":"12783","DOI":"10.1074\/jbc.271.22.12783","article-title":"Physical association of Gi2alpha with interleukin-8 receptors","volume":"271","author":"Damaj","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"issue":"34","key":"10.1016\/j.pharmthera.2022.108257_bb0145","doi-asserted-by":"crossref","first-page":"20540","DOI":"10.1074\/jbc.271.34.20540","article-title":"Diverging signal transduction pathways activated by Interleukin 8 (IL-8) and related chemokines in human neutrophils","volume":"271","author":"Damaj","year":"1996","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0150","first-page":"271","article-title":"Surgical manipulation compromises leukocyte mobilization responses and inflammation after experimental cerebral ischemia in mice","volume":"7","author":"Denes","year":"2013","journal-title":"Frontiers in Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1046\/j.1523-1747.2000.00034.x","article-title":"Delayed wound healing in CXCR2 knockout mice","volume":"115","author":"Devalaraja","year":"2000","journal-title":"The Journal of Investigative Dermatology"},{"issue":"Supplement_1","key":"10.1016\/j.pharmthera.2022.108257_bb0160","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab724.3333","article-title":"IL-8 promotes the calcification of human aortic valve interstitial cells, which is prevented through antagonizing CXCR1 and CXCR2 receptors","volume":"42","author":"Dhayni","year":"2021","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108257_bb0165","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.110.961714","article-title":"Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis","volume":"122","author":"Drechsler","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/bbrc.1998.8499","article-title":"Endothelial Cells Differentially Express Functional CXC-Chemokine Receptor-4 (CXCR-4\/Fusin) under the Control of Autocrine Activity and Exogenous Cytokines","volume":"247","author":"Feil","year":"1998","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0175","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1172\/JCI87491","article-title":"The extracellular matrix in myocardial injury, repair, and remodeling","volume":"127","author":"Frangogiannis","year":"2017","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1189\/jlb.0504306","article-title":"Impaired interleukin-8- and GROalpha-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia","volume":"77","author":"Fuhler","year":"2005","journal-title":"Journal of Leukocyte Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0185","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.intimp.2013.06.034","article-title":"Neutrophil cell surface receptors and their intracellular signal transduction pathways","volume":"17","author":"Futosi","year":"2013","journal-title":"International Immunopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0190","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cyto.2004.12.014","article-title":"Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia","volume":"30","author":"Garau","year":"2005","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0195","first-page":"35","article-title":"Development of a systemically-active dual CXCR1\/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat","volume":"17","author":"Garau","year":"2006","journal-title":"European Cytokine Network"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108257_bb0200","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1128\/MCB.01304-08","article-title":"A role for a CXCR2\/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability","volume":"29","author":"Gavard","year":"2009","journal-title":"Molecular and Cellular Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108257_bb0205","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1161\/01.ATV.0000188554.49745.9e","article-title":"Transfer of endothelial progenitor and bone marrow cells influences atherosclerotic plaque size and composition in apolipoprotein E knockout mice","volume":"25","author":"George","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0210","doi-asserted-by":"crossref","first-page":"C957","DOI":"10.1152\/ajpcell.00451.2005","article-title":"Interleukin-8: Novel roles in human airway smooth muscle cell contraction and migration","volume":"291","author":"Govindaraju","year":"2006","journal-title":"American Journal of Physiology. Cell Physiology"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0215","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1465-9921-9-76","article-title":"The effects of interleukin-8 on airway smooth muscle contraction in cystic fibrosis","volume":"9","author":"Govindaraju","year":"2008","journal-title":"Respiratory Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0220","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 axis in cancer and inflammatory diseases","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/ATVBAHA.109.184382","article-title":"Human IL-8 regulates smooth muscle cell VCAM-1 expression in response to endothelial cells exposed to atheroprone flow","volume":"29","author":"Hastings","year":"2009","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0230","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cyto.2015.01.002","article-title":"The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects","volume":"72","author":"Hastrup","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0235","article-title":"Kr\u00fcppel-Like factor 15 modulates CXCL1\/CXCR2 signaling-mediated inflammatory response contributing to angiotensin II-induced cardiac remodeling","volume":"9","author":"He","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108257_bb0240","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1074\/jbc.M208231200","article-title":"Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2","volume":"278","author":"Heidemann","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0245","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1114\/1.1467926","article-title":"The cytoskeleton under external fluid mechanical forces: hemodynamic forces acting on the endothelium","volume":"30","author":"Helmke","year":"2002","journal-title":"Annals of Biomedical Engineering"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0250","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1161\/01.ATV.0000129537.72553.73","article-title":"Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model","volume":"24","author":"Henke","year":"2004","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108257_bb0255","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1161\/STROKEAHA.115.010620","article-title":"Role of neutrophils in exacerbation of brain injury after focal cerebral ischemia in hyperlipidemic mice","volume":"46","author":"Herz","year":"2015","journal-title":"Stroke"},{"issue":"5025","key":"10.1016\/j.pharmthera.2022.108257_bb0260","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1840701","article-title":"Structure and functional expression of a human interleukin-8 receptor","volume":"253","author":"Holmes","year":"1991","journal-title":"Science (New York, N.Y.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.scr.2014.12.001","article-title":"A critical role of CXCR2 PDZ-mediated interactions in endothelial progenitor cell homing and angiogenesis","volume":"14","author":"Hou","year":"2015","journal-title":"Stem Cell Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108257_bb0270","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/01.RES.0000259043.42571.68","article-title":"Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury","volume":"100","author":"Hristov","year":"2007","journal-title":"Circulation Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0275","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0014-5793(95)00397-R","article-title":"A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated activation of p42\/p44 MAP-kinase (ERK-2)","volume":"364","author":"Jones","year":"1995","journal-title":"FEBS Letters"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108257_bb0280","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.93.13.6682","article-title":"Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2","volume":"93","author":"Jones","year":"1996","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0285","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s13063-017-2210-2","article-title":"CXCR2 Inhibition - a novel approach to treating CoronAry heart DiseAse (CICADA): Study protocol for a randomised controlled trial","volume":"18","author":"Joseph","year":"2017","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0290","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/bcp.12724","article-title":"The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions","volume":"80","author":"Jurcevic","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0295","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1248\/bpb.34.120","article-title":"Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats","volume":"34","author":"Kim","year":"2011","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0300","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pupt.2015.02.001","article-title":"The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD","volume":"31","author":"Kirsten","year":"2015","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108257_bb0305","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1073\/pnas.94.7.3052","article-title":"Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases","volume":"94","author":"Knall","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0310","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1074\/jbc.271.5.2832","article-title":"Interleukin-8 regulation of the Ras\/Raf\/mitogen-activated protein kinase pathway in human neutrophils","volume":"271","author":"Knall","year":"1996","journal-title":"The Journal of Biological Chemistry"},{"issue":"5089","key":"10.1016\/j.pharmthera.2022.108257_bb0315","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1126\/science.1281554","article-title":"Interleukin-8 as a macrophage-derived mediator of angiogenesis","volume":"258","author":"Koch","year":"1992","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0320","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cyto.2018.03.031","article-title":"CXCL8 hyper-signaling in the aortic abdominal aneurysm","volume":"108","author":"Kokje","year":"2018","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108257_bb0325","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.22471","article-title":"Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia\/reperfusion in mice","volume":"48","author":"Kuboki","year":"2008","journal-title":"Hepatology (Baltimore Md.)"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0330","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.V85.2.522.522","article-title":"Diverging signal transduction pathways activated by interleukin-8 and related chemokines in human neutrophils: Interleukin-8, but not NAP-2 or GRO alpha, stimulates phospholipase D activity","volume":"85","author":"L\u2019Heureux","year":"1995","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0335","first-page":"3369","article-title":"IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis","volume":"170","author":"Li","year":"2003","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0340","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1006\/mvre.2002.2442","article-title":"Interleukin-8-induced proliferation, survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein endothelial cells","volume":"64","author":"Li","year":"2002","journal-title":"Microvascular Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0345","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0006-291X(02)00318-2","article-title":"CXCL8(3\u201373)K11R\/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8\/IL-8","volume":"293","author":"Li","year":"2002","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108257_bb0350","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.jbiomech.2004.09.030","article-title":"Molecular basis of the effects of shear stress on vascular endothelial cells","volume":"38","author":"Li","year":"2005","journal-title":"Journal of Biomechanics"},{"issue":"7823","key":"10.1016\/j.pharmthera.2022.108257_bb0355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-020-2492-5","article-title":"Structural basis of CXC chemokine receptor 2 activation and signalling","volume":"585","author":"Liu","year":"2020","journal-title":"Nature"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2022.108257_bb0360","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0014-5793(94)80454-0","article-title":"Both interleukin-8 receptors independently mediate chemotaxis: Jurkat cells transfected with IL-8R1 or IL-8R2 migrate in response to IL-8, GRO\u03b1 and NAP-2","volume":"341","author":"Loetscher","year":"1994","journal-title":"FEBS Letters"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0365","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/pr.109.002436","article-title":"Beyond desensitization: physiological relevance of arrestin-dependent signaling","volume":"62","author":"Luttrell","year":"2010","journal-title":"Pharmacological Reviews"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108257_bb0370","first-page":"7337","article-title":"Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers","volume":"183","author":"Mart\u00ednez Mu\u00f1oz","year":"2009","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108257_bb0375","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1189\/jlb.0405182","article-title":"Cytokines and cardiovascular disease","volume":"78","author":"Mehra","year":"2005","journal-title":"Journal of Leukocyte Biology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0380","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/00498250600646517","article-title":"Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog","volume":"36","author":"Midgley","year":"2006","journal-title":"Xenobiotica; the Fate of Foreign Compounds in Biological Systems"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107799","article-title":"Role of inflammatory chemokines in hypertension","volume":"223","author":"Mikolajczyk","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108257_bb0390","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/cyto.1998.0465","article-title":"Cxc chemokine receptor expression on human endothelial cells","volume":"11","author":"Murdoch","year":"1999","journal-title":"Cytokine"},{"issue":"5025","key":"10.1016\/j.pharmthera.2022.108257_bb0395","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1126\/science.1891716","article-title":"Cloning of complementary DNA encoding a functional human interleukin-8 receptor","volume":"253","author":"Murphy","year":"1991","journal-title":"Science (New York, N.Y.)"},{"issue":"23","key":"10.1016\/j.pharmthera.2022.108257_bb0400","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1161\/01.CIR.0000148824.93600.F3","article-title":"Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines","volume":"110","author":"Nabah","year":"2004","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108257_bb0405","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: A randomized, placebo-controlled clinical trial","volume":"42","author":"Nair","year":"2012","journal-title":"Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0410","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.4049\/jimmunol.0900305","article-title":"Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer","volume":"183","author":"Nasser","year":"2009","journal-title":"The Journal of Immunology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0415","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.transproceed.2007.05.018","article-title":"Protective effect of an inhibitor of interleukin-8 (meraxin) from ischemia and reperfusion injury in a rat model of kidney transplantation","volume":"39","author":"Neri","year":"2007","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0420","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/jpet.114.221358","article-title":"Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist","volume":"353","author":"Nicholls","year":"2015","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0425","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00380-018-1301-7","article-title":"Chemokine (C-X-C motif) receptor 2 blockade by SB265610 inhibited angiotensin II-induced abdominal aortic aneurysm in Apo E-\/- mice","volume":"34","author":"Nie","year":"2019","journal-title":"Heart and Vessels"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108257_bb0430","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2213-2600(16)30227-2","article-title":"Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: A randomised, double-blind, placebo-controlled trial","volume":"4","author":"O\u2019Byrne","year":"2016","journal-title":"The Lancet. Respiratory Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108257_bb0435","doi-asserted-by":"crossref","first-page":"L434","DOI":"10.1152\/ajplung.00156.2019","article-title":"Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia","volume":"317","author":"Oliveira","year":"2019","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0440","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3389\/fimmu.2017.01917","article-title":"Intravital microscopic evaluation of the effects of a CXCR2 antagonist in a model of liver ischemia reperfusion injury in mice","volume":"8","author":"de Oliveira","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0445","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/cei.12488","article-title":"A pilot study on reparixin, a CXCR1\/2 antagonist, to assess safety and efficacy in attenuating ischaemia-reperfusion injury and inflammation after on-pump coronary artery bypass graft surgery","volume":"180","author":"Opfermann","year":"2015","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2013.04.006","article-title":"CXC chemokine KC fails to induce neutrophil infiltration and neoangiogenesis in a mouse model of myocardial infarction","volume":"60","author":"Oral","year":"2013","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108257_bb0455","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1091\/mbc.e07-01-0004","article-title":"Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8\/CXCL8) is required for IL-8\/CXCL8-induced endothelial permeability","volume":"18","author":"Petreaca","year":"2007","journal-title":"Molecular Biology of the Cell"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0460","doi-asserted-by":"crossref","DOI":"10.1111\/dom.14770","article-title":"Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial","author":"Piemonti","year":"2022","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0465","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.biochem.67.1.653","article-title":"G protein\u2013coupled receptor kinases","volume":"67","author":"Pitcher","year":"1998","journal-title":"Annual Review of Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0470","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/08923973.2019.1616753","article-title":"Inhibitory effect of recombinant human CXCL8(3-72)K11R\/G31P on atherosclerotic plaques in a mouse model of atherosclerosis","volume":"41","author":"Qin","year":"2019","journal-title":"Immunopharmacology and Immunotoxicology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0475","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.4049\/jimmunol.1201114","article-title":"The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions","volume":"189","author":"Raghuwanshi","year":"2012","journal-title":"The Journal of Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108257_bb0480","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1074\/jbc.M409592200","article-title":"Activation of CD38 by interleukin-8 signaling regulates intracellular Ca2+ level and motility of lymphokine-activated killer cells","volume":"280","author":"Rah","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"issue":"49","key":"10.1016\/j.pharmthera.2022.108257_bb0485","doi-asserted-by":"crossref","first-page":"35039","DOI":"10.1074\/jbc.M113.479113","article-title":"Biased agonism as a mechanism for differential signaling by chemokine receptors","volume":"288","author":"Rajagopal","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108257_bb0490","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123. A phase 2 Proof-of-concept trial for chronic obstructive pulmonary disease","volume":"191","author":"Rennard","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0495","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6107(02)00052-4","article-title":"Fluid shear stress and the vascular endothelium: For better and for worse","volume":"81","author":"Resnick","year":"2003","journal-title":"Progress in Biophysics and Molecular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0500","first-page":"2904","article-title":"Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation","volume":"170","author":"Richardson","year":"2003","journal-title":"Journal of Immunology (Baltimore, Md.\u202f: 1950)"},{"issue":"37","key":"10.1016\/j.pharmthera.2022.108257_bb0505","doi-asserted-by":"crossref","first-page":"23830","DOI":"10.1074\/jbc.273.37.23830","article-title":"Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation","volume":"273","author":"Richardson","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0510","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/1744666X.2014.894886","article-title":"The CXCL8\/IL-8 chemokine family and its receptors in inflammatory diseases","volume":"10","author":"Russo","year":"2014","journal-title":"Expert Review of Clinical Immunology"},{"issue":"Pt 23","key":"10.1016\/j.pharmthera.2022.108257_bb0515","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1242\/jcs.01398","article-title":"The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis","volume":"117","author":"Sai","year":"2004","journal-title":"Journal of Cell Science"},{"issue":"13","key":"10.1016\/j.pharmthera.2022.108257_bb0520","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1096\/fj.99-0963com","article-title":"Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells","volume":"14","author":"Salcedo","year":"2000","journal-title":"FASEB Journal\u202f: Official Publication of the Federation of American Societies for Experimental Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108257_bb0525","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1161\/ATVBAHA.107.161224","article-title":"Chemokines in vascular dysfunction and remodeling","volume":"28","author":"Schober","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0530","doi-asserted-by":"crossref","first-page":"L1094","DOI":"10.1152\/ajplung.2001.280.6.L1094","article-title":"IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways","volume":"280","author":"Schraufstatter","year":"2001","journal-title":"American Journal of Physiology. Lung Cellular and Molecular Physiology"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.540878","article-title":"Involvement of CXCL1\/CXCR2 during microglia activation following inflammation-sensitized hypoxic-ischemic brain injury in neonatal rats","volume":"11","author":"Serdar","year":"2020","journal-title":"Frontiers in Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0540","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.mvr.2011.06.011","article-title":"CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation","volume":"82","author":"Singh","year":"2011","journal-title":"Microvascular Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0545","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.4049\/jimmunol.1301875","article-title":"G protein\u2013coupled receptor kinase-6 interacts with activator of G protein signaling-3 to regulate CXCR2-mediated cellular functions","volume":"192","author":"Singh","year":"2014","journal-title":"The Journal of Immunology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0550","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0969-2126(99)80022-7","article-title":"Structure of a CXC chemokine-receptor fragment in complex with interleukin-8","volume":"7","author":"Skelton","year":"1999","journal-title":"Structure (London, England: 1993)"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0555","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/emmm.201201717","article-title":"Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes","volume":"5","author":"Soehnlein","year":"2013","journal-title":"EMBO Molecular Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0560","doi-asserted-by":"crossref","first-page":"391","DOI":"10.6061\/clinics\/2013(03)OA17","article-title":"Blockade of CXCR1\/2 chemokine receptors protects against brain damage in ischemic stroke in mice","volume":"68","author":"da Sousa","year":"2013","journal-title":"Clinics (S\u00e3o Paulo, Brazil)"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0565","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj.bjp.0705862","article-title":"Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury","volume":"143","author":"Souza","year":"2004","journal-title":"British Journal of Pharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108257_bb0570","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood.V84.11.3895.bloodjournal84113895","article-title":"Activation of phospholipase D by interleukin-8 in human neutrophils","volume":"84","author":"Sozzani","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2022.108257_bb0575","doi-asserted-by":"crossref","first-page":"7092151","DOI":"10.1155\/2019\/7092151","article-title":"Vascular inflammation and oxidative stress: major triggers for cardiovascular disease","volume":"2019","author":"Steven","year":"2019","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108257_bb0580","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1152\/japplphysiol.00974.2007","article-title":"Inhibition of CXCR2 attenuates bronchial angiogenesis in the ischemic rat lung","volume":"104","author":"Sukkar","year":"2008","journal-title":"Journal of Applied Physiology (Bethesda, MD: 1985)"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0585","doi-asserted-by":"crossref","DOI":"10.1590\/acb360105","article-title":"Inhibition of CXCR2 alleviates the development of abdominal aortic aneurysm in Apo E-\/- mice","volume":"36","author":"Sun","year":"2021","journal-title":"Acta Cir\u00fargica Brasileira"},{"issue":"19","key":"10.1016\/j.pharmthera.2022.108257_bb0590","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1161\/01.CIR.0000093192.72099.9A","article-title":"Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: Recruitment of potentially damaging neutrophils and direct myocardial protection","volume":"108","author":"Tarzami","year":"2003","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108257_bb0595","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1158\/1078-0432.CCR-20-1319","article-title":"IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy","volume":"27","author":"Teijeira","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0600","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1006\/bbrc.1995.2903","article-title":"PI 3-kinase-dependent and independent chemotaxis of human neutrophil leukocytes","volume":"217","author":"Thelen","year":"1995","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108257_bb0605","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000441529","article-title":"The CXCR2 Gene polymorphism is associated with stroke in patients with essential hypertension","volume":"5","author":"Timasheva","year":"2015","journal-title":"Cerebrovascular Diseases Extra"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108257_bb0610","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/01.TP.0000122231.43653.CC","article-title":"Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation","volume":"77","author":"Turunen","year":"2004","journal-title":"Transplantation"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2022.108257_bb0615","first-page":"125","article-title":"The interleukin-8 (IL-8\/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats","volume":"13","author":"Villa","year":"2007","journal-title":"Molecular Medicine (Cambridge Mass.)"},{"issue":"20","key":"10.1016\/j.pharmthera.2022.108257_bb0620","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/eurheartj\/ehy085","article-title":"CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration","volume":"39","author":"Wang","year":"2018","journal-title":"European Heart Journal"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108257_bb0625","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/CIRCULATIONAHA.115.020754","article-title":"Genetic and pharmacologic inhibition of the chemokine receptor CXCR2 prevents experimental hypertension and vascular dysfunction","volume":"134","author":"Wang","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.pharmthera.2022.108257_bb0630","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Waugh","year":"2008","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"42","key":"10.1016\/j.pharmthera.2022.108257_bb0635","doi-asserted-by":"crossref","first-page":"16278","DOI":"10.1073\/pnas.0804017105","article-title":"Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment","volume":"105","author":"Weber","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108257_bb0640","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1161\/01.ATV.0000142812.03840.6f","article-title":"Chemokines: Key regulators of mononuclear cell recruitment in atherosclerotic vascular disease","volume":"24","author":"Weber","year":"2004","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108257_bb0645","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1111\/bph.13818","article-title":"Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?","volume":"174","author":"Welsh","year":"2017","journal-title":"British Journal of Pharmacology"},{"issue":"17","key":"10.1016\/j.pharmthera.2022.108257_bb0650","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1074\/jbc.273.17.10095","article-title":"Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration","volume":"273","author":"White","year":"1998","journal-title":"The Journal of Biological Chemistry"},{"issue":"5117","key":"10.1016\/j.pharmthera.2022.108257_bb0655","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1126\/science.8316840","article-title":"G protein-coupled signal transduction pathways for interleukin-8","volume":"261","author":"Wu","year":"1993","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108257_bb0660","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/ATVBAHA.110.220202","article-title":"Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E\u2212\/\u2212 Mice","volume":"31","author":"Wu","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108257_bb0665","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/bi961999z","article-title":"Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties\u2020","volume":"36","author":"Wuyts","year":"1997","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0670","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1014836211643","article-title":"Inhibition of IL-8-mediated MAPK activation in human neutrophils by beta1 integrin ligands","volume":"26","author":"Xythalis","year":"2002","journal-title":"Inflammation"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0675","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cyto.2010.09.007","article-title":"CXCR1 and CXCR2 are novel mechano-sensors mediating laminar shear stress-induced endothelial cell migration","volume":"53","author":"Zeng","year":"2011","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0680","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/HYPERTENSIONAHA.120.14698","article-title":"Chemokine receptor CXCR-2 initiates atrial fibrillation by triggering monocyte mobilization in mice","volume":"76","author":"Zhang","year":"2020","journal-title":"Hypertension (Dallas, Tex.: 1979)"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108257_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2019.165551","article-title":"Chronic inhibition of chemokine receptor CXCR2 attenuates cardiac remodeling and dysfunction in spontaneously hypertensive rats","volume":"1865","author":"Zhang","year":"2019","journal-title":"Biochimica Et Biophysica Acta. Molecular Basis of Disease"},{"issue":"19","key":"10.1016\/j.pharmthera.2022.108257_bb0690","doi-asserted-by":"crossref","first-page":"11272","DOI":"10.1111\/jcmm.15694","article-title":"Selective blocking of CXCR2 prevents and reverses atrial fibrillation in spontaneously hypertensive rats","volume":"24","author":"Zhang","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108257_bb0695","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1038\/s41598-017-15867-8","article-title":"Chemokines protect vascular smooth muscle cells from cell death induced by cyclic mechanical stretch","volume":"7","author":"Zhao","year":"2017","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108257_bb0700","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jss.2009.04.047","article-title":"A novel ELR-CXC chemokine antagonist reduces intestinal ischemia reperfusion-induced mortality, and local and remote organ injury","volume":"162","author":"Zhao","year":"2010","journal-title":"The Journal of Surgical Research"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:33:45Z","timestamp":1759012425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":141,"alternative-id":["S0163725822001516"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108257","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108257"}}